Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962699 | 0.88 | THRA (0.39) | THRATHRBOPRK1OPRM1OPRD1 | |
| SCHEMBL3147512 | 0.81 | THRA (0.37) | THRATHRBPTGER1 | |
| SCHEMBL4206031 | 0.81 | PTGER1 (0.35) | THRATHRBPTGER1 | |
| SCHEMBL4213025 | 0.81 | PTGER1 (0.35) | THRATHRBOPRK1OPRM1OPRD1 | |
| SCHEMBL4215714 | 0.81 | THRB (0.43) | THRATHRB | |
| SCHEMBL3155899 | 0.80 | OPRK1 (0.39) | THRATHRBOPRK1OPRM1OPRD1 | |
| SCHEMBL4961897 | 0.80 | PTGER1 (0.33) | THRATHRBPTGER1 | |
| SCHEMBL4214479 | 0.79 | PTGDR2 (0.37) | OPRK1OPRM1OPRD1PTGER1 | |
| SCHEMBL3158226 | 0.79 | PPARA (0.41) | THRATHRBPTGER1 | |
| SCHEMBL3156007 | 0.78 | THRA (0.39) | THRATHRBOPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRA 14/4885THRB 41/4885OPRK1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.